The fact that multiple myeloma cells treated with carfilzomib showed increased LONP1 expression indicates that the up-regulation of this mitoprotease is a result of proteasome inhibition, and not in response to LonP1 inhibition (Figure 3C and Supplementary Figure S1). Here, LONP1 is linked to plasma cell myeloma.